logo-small.jpg
Oblato acquires all rights to glioblastoma drug from OMRF
29 oct. 2018 11h21 HE | Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...
logo-small.jpg
Novel treatment of hemophilia: OMRF enters license agreement with Shanghai RAAS Blood Products
13 févr. 2018 15h02 HE | Oklahoma Medical Research Foundation
OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation has entered a license agreement with Shanghai RAAS Blood Products Co., Ltd. Under the agreement, Shanghai...
New tools for predicting lupus flares now one step closer to market
27 nov. 2017 15h23 HE | Progentec Diagnostics, Inc.
OKLAHOMA CITY, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Lead investor i2E, along with Chicago-based OCA Ventures and Mayo Clinic Ventures, has funded the first round of investment to assist Progentec in...